title: Deep molecular response by IFN-α and dasatinib combination in a patient with T315I-mutated chronic myeloid leukemia.
abstract: The T315I mutation is especially challenging as it confers resistance to all first- and second-generation tyrosine kinase inhibitors. We present here a chronic myeloid leukemia patient harboring the T315I and E255V BCR-ABL1 mutation successfully achieved deep molecular response with a combined treatment of dasatinib and IFN-α. To our knowledge, this is the second case of a T315I-bearing chronic myeloid leukemia patient displaying satisfactory response to the combination therapy of dasatinib and IFN-α.
authors.affiliation: Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.|Jiangsu Institute of Hematology, Key Laboratory of Thrombosis & Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Zhou
authors.affiliation: Jiangsu Institute of Hematology, Key Laboratory of Thrombosis & Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, China.
authors.forename: Huiping
authors.initials: H
authors.lastname: Shi
authors.affiliation: Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Shenghua
authors.initials: S
authors.lastname: Jiang
authors.affiliation: Jiangsu Institute of Hematology, Key Laboratory of Thrombosis & Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, China.
authors.forename: Changgeng
authors.initials: C
authors.lastname: Ruan
authors.affiliation: Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000069439:Dasatinib / Q000008:administration & dosage*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: C581634:BCR-ABL1 fusion protein, human; D016898:Interferon-alpha; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib
keywords: T315I; chronic myelogenous leukemia; dasatinib; interferon-α